RSS-Feed abonnieren
DOI: 10.1055/s-0031-1273397
© Georg Thieme Verlag KG Stuttgart · New York
Effektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien
Efficacy of Antipsychotic Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder – A Meta-Analysis of Double-Blind, Randomised, Placebo-Controlled TrialsPublikationsverlauf
Publikationsdatum:
01. August 2011 (online)

Zusammenfassung
Da bei der Zwangsstörung nur etwa 40 – 60 % aller Patienten auf Serotonin-Wiederaufnahmehemmer (SRIs) ansprechen, kommt der Evaluation additiver Therapien bei Behandlungsresistenz eine hohe klinische Relevanz zu. Mittels systematischer Literaturrecherche wurden alle doppelblinden, randomisierten, placebokontrollierten Studien erfasst, die die Wirksamkeit einer SRI-Antipsychotika-Kombinationstherapie bei therapieresistenten Zwangsstörungen evaluiert haben. 11 Studien mit insgesamt 356 Teilnehmern wurden identifiziert. Nach der Augmentationsbehandlung erfüllten in den Interventionsgruppen (SRI + Antipsychotikum) signifikant mehr Probanden das Responder-Kriterium (Reduktion im Yale-Brown Obsessive Compulsive Scale [Y-BOCS] ≥ 35 %) als in den Kontrollgruppen (SRI + Placebo) (relatives Risiko = 2,16). Die Subgruppenanalyse zeigte nur für Risperidon eine signifikante Effektivität. Weitere signifikante Unterschiede fanden sich hinsichtlich der Dosierung der Antipsychotika und der Dauer der SRI-Medikation vor der Augmentationsphase.
Abstract
Only 40 – 60 % of all patients with obsessive-compulsive disorder (OCD) respond to serotonin reuptake inhibitors (SRIs). Therefore, the evaluation of additive treatment in the presence of treatment resistance has high clinical relevance. All double-blind, randomised, placebo-controlled trials that evaluated the efficacy of a combination therapy of SRIs and antipsychotics in treatment-resistant OCD were identified by systematic literature searches and combined in a meta-analysis. 11 studies with a total of 356 treatment-resistant patients were included. After the augmentation, significantly more subjects in the intervention groups (SRI + antipsychotic) fulfilled the response criterion (reduction in the Yale-Brown obsessive compulsive scale [Y-BOCS] ≥ 35 %) than in the control groups (SRI + placebo) (relative risk = 2.16). The subgroup analysis showed significant efficacy only for risperidone. Further significant differences have been found regarding the antipsychotic dosage and the SRI-treatment duration before the augmentation.
Schlüsselwörter
Zwangsstörung - Antipsychotika - Serotonin-Wiederaufnahmehemmer - Therapieresistenz - Metaanalyse
Keywords
obsessive-compulsive disorder - antipsychotics - serotonin reuptake inhibitors - treatment resistance - meta-analysis
Literatur
- 1 American Psychiatric Association (APA) .Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association. Available online at 2007 http://http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm 
            Reference Ris Wihthout Link
- 2 
            Bandelow B, Zohar J, Hollander E et al. 
            World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
            pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress
            disorders – first revision. 
            World J Biol Psychiatry. 
            2008; 
            9 
            248-312 
            
            Reference Ris Wihthout Link
- 3 National Institute for Clinical Excellence (NICE) .Obsessive compulsive disorder: Core interventions in the treatment of obsessive compulsive
            disorder and body dysmorphic disorder. NICE; 2006 
            Reference Ris Wihthout Link
- 4 
            Cottraux J, Bouvard M A, Milliery M. 
            Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive
            disorder. 
            Cogn Behav Ther. 
            2005; 
            34 
            185-192 
            
            Reference Ris Wihthout Link
- 5 
            Eddy K T, Dutra L, Bradley R et al. 
            A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive
            disorder. 
            Clin Psychol Rev. 
            2004; 
            24 
            1011-1030 
            
            Reference Ris Wihthout Link
- 6 
            Soomro G M, Altman D, Rajagopal S et al. 
            Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive
            disorder (OCD). 
            Cochrane Database Syst Rev. 
            2008; 
            1 
            CD001765 
            
            Reference Ris Wihthout Link
- 7 
            Fineberg N A, Tonnoir B, Lemming O et al. 
            Escitalopram prevents relapse of obsessive-compulsive disorder. 
            Eur Neuropsychopharmacol. 
            2007; 
            17 
            430-439 
            
            Reference Ris Wihthout Link
- 8 
            Stein D J, Andersen E W, Tonnoir B et al. 
            Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced,
            fixed-dose, 24-week study. 
            Curr Med Res Opin. 
            2007; 
            23 
            701-711 
            
            Reference Ris Wihthout Link
- 9 
            Dell’Osso B, Nestadt G, Allen A et al. 
            Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive
            disorder: a critical review. 
            J Clin Psychiatry. 
            2006; 
            67 
            600-610 
            
            Reference Ris Wihthout Link
- 10 
            Kriegebaum C, Gutknecht L, Schmitt A et al. 
            Serotonin Kompakt – Teil 2: Verhaltensgenetik und Psychopathologie. 
            Fortschr Neurol Psychiatr. 
            2010; 
            78 
            332-342 
            
            Reference Ris Wihthout Link
- 11 
            Schmauss M, Messer T. 
            Therapieresistente Depressionen – Teil 1: Definition und Ursachen, Prädiktion des
            Therapieerfolgs, psychotherapeutische Behandlungsstrategien. 
            Fortschr Neurol Psychiatr. 
            2010; 
            78 
            45-57 
            
            Reference Ris Wihthout Link
- 12 
            Pallanti S, Hollander E, Bienstock C et al. 
            Treatment non-response in OCD: methodological issues and operational definitions. 
            Int J Neuropsychopharmacol. 
            2002; 
            5 
            181-191 
            
            Reference Ris Wihthout Link
- 13 
            Pallanti S, Quercioli L. 
            Treatment-refractory obsessive-compulsive disorder: methodological issues, operational
            definitions and therapeutic lines. 
            Prog Neuropsychopharmacol Biol Psychiatry. 
            2006; 
            30 
            400-412 
            
            Reference Ris Wihthout Link
- 14 
            Goodman W K, Price L H, Rasmussen S A et al. 
            Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). 
            Arch Gen Psychiatry. 
            1989; 
            46 
            1006-1011 
            
            Reference Ris Wihthout Link
- 15 
            Denys D, Megen H J, derWee van N et al. 
            A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive
            disorder. 
            J Clin Psychiatry. 
            2004; 
            65 
            37-43 
            
            Reference Ris Wihthout Link
- 16 
            Fallon van B A, Liebowitz M R, Campeas R et al. 
            Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine:
            a placebo-controlled study. 
            Arch Gen Psychiatry. 
            1998; 
            55 
            918-924 
            
            Reference Ris Wihthout Link
- 17 
            Ninan P T, Koran L M, Kiev A et al. 
            High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive
            disorder: a multicenter double-blind trial. 
            J Clin Psychiatry. 
            2006; 
            67 
            15-22 
            
            Reference Ris Wihthout Link
- 18 
            Pallanti S, Quercioli L, Koran L M. 
            Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open
            trial. 
            J Clin Psychiatry. 
            2002; 
            63 
            796-801 
            
            Reference Ris Wihthout Link
- 19 
            Fink G R. 
            Tiefe Hirnstimulation in Neurologie und Psychiatrie. 
            Fortschr Neurol Psychiat. 
            2010; 
            78 
            69 
            
            Reference Ris Wihthout Link
- 20 
            Kordon A, Zurowski B, Wahl K et al. 
            Evidenzbasierte Pharmakotherapie und andere somatische Therapieverfahren bei Zwangsstörungen
            – State of the art. 
            Nervenarzt. 
            2011; 
            82 
            319-324 
            
            Reference Ris Wihthout Link
- 21 
            Denys D, Zohar J, Westenberg H G. 
            The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. 
            J Clin Psychiatry. 
            2004; 
            65 (Suppl 14) 
            11-17 
            
            Reference Ris Wihthout Link
- 22 
            Goddard A W, Shekhar A, Whiteman A F et al. 
            Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. 
            Drug Discov Today. 
            2008; 
            13 
            325-332 
            
            Reference Ris Wihthout Link
- 23 
            Bloch M H, Landeros-Weisenberger A, Kelmendi B et al. 
            A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive
            disorder. 
            Mol Psychiatry. 
            2006; 
            11 
            622-632 
            
            Reference Ris Wihthout Link
- 24 
            Skapinakis P, Papatheodorou T, Mavreas V. 
            Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant
            obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. 
            Eur Neuropsychopharmacol. 
            2007; 
            17 
            79-93 
            
            Reference Ris Wihthout Link
- 25 
            Falkai P, Wobrock T, Lieberman J et al. 
            World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological
            treatment of schizophrenia, part 2: long-term treatment of schizophrenia. 
            World J Biol Psychiatry. 
            2006; 
            7 
            5-40 
            
            Reference Ris Wihthout Link
- 26 The Cochrance Collaboration .Software Review Manager (RevMan) Version 5.1.1 2011 
            Reference Ris Wihthout Link
- 27 
            Jadad A R, Moore R A, Carroll D et al. 
            Assessing the quality of reports of randomized clinical trials: is blinding necessary?. 
            Control Clin Trials. 
            1996; 
            17 
            1-12 
            
            Reference Ris Wihthout Link
- 28 
            Bystritsky A, Ackerman D L, Rosen R M et al. 
            Olanzapine augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive
            disorder using adjunctive olanzapine: a placebo-controlled trial. 
            J Clin Psychiatry. 
            2004; 
            65 
            565-568 
            
            Reference Ris Wihthout Link
- 29 
            Carey P D, Vythilingum B, Seedat S et al. 
            Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder:
            a double-blind, randomised, placebo-controlled study. 
            BMC Psychiatry. 
            2005; 
            5 
            5 
            
            Reference Ris Wihthout Link
- 30 
            Denys D, Geus de F, Harold J GM et al. 
            A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients
            with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. 
            J Clin Psychiatry. 
            2004; 
            65 
            1040-1048 
            
            Reference Ris Wihthout Link
- 31 
            Erzegovesi S, Guglielimo E, Siliprandi F et al. 
            Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive
            disorder: a double-blind, placebo-controlled study. 
            Eur Neuropsychopharmacol. 
            2005; 
            15 
            69-74 
            
            Reference Ris Wihthout Link
- 32 
            Fineberg N A, Sivakumaran T, Roberts A et al. 
            Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized
            controlled treatment study. 
            Int Clin Psychopharmacol. 
            2005; 
            20 
            223-226 
            
            Reference Ris Wihthout Link
- 33 
            Hollander E, Rossi N B, Sood E et al. 
            Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind,
            placebo-controlled study. 
            Int J Neuropsychopharmacol. 
            2003; 
            6 
            397-401 
            
            Reference Ris Wihthout Link
- 34 
            Kordon A, Wahl K, Koch N et al. 
            Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive
            disorder: a double-blind, randomized, placebo-controlled study. 
            J Clin Psychopharmacol. 
            2008; 
            28 
            550-554 
            
            Reference Ris Wihthout Link
- 35 
            McDougle C J, Epperson C N, Pelton G H et al. 
            A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake
            inhibitor-refractory obsessive-compulsive disorder. 
            Arch Gen Psychiatry. 
            2000; 
            57 
            794-801 
            
            Reference Ris Wihthout Link
- 36 
            McDougle C J, Goodman W K, Leckman J F et al. 
            Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. 
            Arch Gen Psychiatry. 
            1994; 
            51 
            302-308 
            
            Reference Ris Wihthout Link
- 37 
            Muscatello M R, Bruno A, Pandolfo G et al. 
            Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine
            in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled
            study. 
            J Clin Psychopharmacol. 
            2011; 
            31 
            174-179 
            
            Reference Ris Wihthout Link
- 38 
            Shapira N A, Ward H E, Mandoki M et al. 
            A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory
            obsessive-compulsive disorder. 
            Biol Psychiatry. 
            2004; 
            55 
            553-555 
            
            Reference Ris Wihthout Link
- 39 Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1969 
            Reference Ris Wihthout Link
- 40 
            Goodman W K, Storch E A, Geffken G R et al. 
            Obsessive-compulsive disorder in Tourette syndrome. 
            J Child Neurol. 
            2006; 
            21 
            704-714 
            
            Reference Ris Wihthout Link
- 41 
            Bestha D P, Jeevarakshagan S, Madaan V. 
            Management of tics and Tourette’s disorder: an update. 
            Expert Opin Pharmacother. 
            2010; 
            11 
            1813-1822 
            
            Reference Ris Wihthout Link
- 42 
            Komossa K, Depping A M, Meyer M et al. 
            Second-generation antipsychotics for obsessive compulsive disorder. 
            Cochrane Database Syst Rev. 
            2010; 
            12 
            CD008141 
            
            Reference Ris Wihthout Link
- 43 Higgins J PT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 The Cochrane Collaboration; 2009 Available online at http://www.cochrane-handbook.org 
            Reference Ris Wihthout Link
- 44 
            Vulink N C, Denys D, Fluitman S B et al. 
            Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive
            disorder: a randomized, double-blind, placebo-controlled study of 76 patients. 
            J Clin Psychiatry. 
            2009; 
            70 
            1001-1008 
            
            Reference Ris Wihthout Link
- 45 
            Goodwin G, Fleischhacker W, Arango C et al. 
            Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus
            Meeting, March 2008, Nice. 
            Eur Neuropsychopharmacol. 
            2009; 
            19 
            520-532 
            
            Reference Ris Wihthout Link
- 46 
            Li X, May R S, Tolbert L C et al. 
            Risperidone and Haloperidol Augmentation of Serotonin Reuptake Inhibitors in Refractory
            Obsessive-Compulsive Disorder: A crossover study. 
            J Clin Psychiatry. 
            2005; 
            66 
            736-743 
            
            Reference Ris Wihthout Link
- 47 
            Matsunaga H, Nagata T, Hayashida K et al. 
            A long-term trial of the effectiveness and safety of atypical antipsychotic agents
            in augmenting SSRI-refractory obsessive-compulsive disorder. 
            J Clin Psychiatry. 
            2009; 
            70 
            863-868 
            
            Reference Ris Wihthout Link
- 48 
            Kim S W, Shin I S, Kim J M et al. 
            Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking
            atypical antipsychotics: an open-label switch study. 
            J Clin Psychopharmacol. 
            2008; 
            28 
            349-352 
            
            Reference Ris Wihthout Link
- 49 
            Desarkar P, Das A, Nizamie S H. 
            Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. 
            J Clin Psychopharmacol. 
            2007; 
            27 
            305-306 
            
            Reference Ris Wihthout Link
- 50 
            Ke C L, Yen C F, Chen C C et al. 
            Obsessive-compulsive symptoms associated with clozapine and risperidone treatment:
            three case reports and review of the literature. 
            Kaohsiung J Med Sci. 
            2004; 
            20 
            295-301 
            
            Reference Ris Wihthout Link
- 51 
            Lykouras L, Zervas I M, Gournellis R et al. 
            Olanzapine and obsessive-compulsive symptoms. 
            Eur Neuropsychopharmacol. 
            2000; 
            10 
            385-387 
            
            Reference Ris Wihthout Link
- 52 
            Stamouli S, Lykouras L. 
            Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. 
            J Clin Psychopharmacol. 
            2006; 
            26 
            396-400 
            
            Reference Ris Wihthout Link
- 53 
            Kim S W, Shin I S, Kim J M et al. 
            The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive
            symptoms in schizophrenia. 
            Clin Neuropharmacol. 
            2009; 
            32 
            224-226 
            
            Reference Ris Wihthout Link
- 54 
            Metin O, Yazici K, Tot S et al. 
            Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an
            open trial. 
            Hum Psychopharmacol. 
            2003; 
            18 
            463-467 
            
            Reference Ris Wihthout Link
- 55 
            Marek G J, Carpenter L L, McDougle C J et al. 
            Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors
            in neuropsychiatric disorders. 
            Neuropsychopharmacology. 
            2003; 
            28 
            402-412 
            
            Reference Ris Wihthout Link
- 56 
            Koran L M, Gamel N N, Choung H W et al. 
            Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind
            discontinuation. 
            J Clin Psychiatry. 
            2005; 
            66 
            515-520 
            
            Reference Ris Wihthout Link
- 57 
            Bandelow B. 
            The medical treatment of obsessive-compulsive disorder and anxiety. 
            CNS Spectr. 
            2008; 
            13 
            37-46 
            
            Reference Ris Wihthout Link
- 58 
            Maina G, Pessina E, Albert U et al. 
            8-week, singleblind, randomized trial comparing risperidone versus olanzapine augmentation
            of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. 
            Eur Neuropsychopharmacol. 
            2008; 
            18 
            364-372 
            
            Reference Ris Wihthout Link
- 59 
            Selvi Y, Atli A, Aydin A et al. 
            The comparison of aripiprazole and risperidone augmentation in selective serotonin
            reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised
            study. 
            Hum Psychopharmacol. 
            2011; 
            26 
            51-57 
            
            Reference Ris Wihthout Link
Dr. Markus Dold
         Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar
         der TU München
         
         Ismaninger Straße 22
         
         81675 München
         
         eMail: markus.dold@lrz.tum.de
         
         
 
     
      
    